LivaNova has completed the CORE-VNS study, assessing outcomes via real-world evidence on the use of the VNS Therapy device in ...

NeuroPace's RNS System trial showed a strong safety profile and subgroup efficacy in drug-resistant epilepsy, prompting FDA ...

Eamonn started playing rugby when he was six years old and now plays in the second and third team for Huel Tring Rugby.

Emma Evens, 34, from Essex, suffers from tonic clonic seizures, which cause her to stiffen and convulse and can happen at any moment ...

Following its successful US launch and FDA clearance, Empatica is proud to announce that EpiMonitor, its pioneering epilepsy ...

The Ottawa Hospital is creating a comprehensive Epilepsy Program — a one-stop shop that will be a change-maker for patients.

NeuroPace (NASDAQ:NPCE) stock drops as the company's NAUTILUS study for RNS System misses the primary endpoint for the ...

Empatica announced today that it received CE mark approval for its EpiMonitor epilepsy monitoring solution. EpiMonitor, a ...

"We view the totality of the data in the NAUTILUS study as a meaningful catalyst that adds to the growing body of evidence and momentum in our business,” said Joel Becker, Chief Executive Officer.

NeuroPace has reported the initial primary endpoint one-year outcomes from the NAUTILUS trial of the RNS System.

Shares of NeuroPace sank after the company said the study of its RNS system for treating drug-resistant idiopathic generalized epilepsy missed a primary endpoint. The stock was down 37% at $11.15 in ...

Amidst alarming cuts in cancer research funding, there is new urgency for individuals to take control of their health.  Radical Remission Project, a global education movement, and The Radical ...